Roche wins EU approval for hemophilia drug Hemlibra
ZURICH: Swiss group Roche said the European Commission has approved its drug Hemlibra for people with hemophilia A who have developed resistance to standard treatments.
The approval was expected after a panel recommended it last month. The drug was already approved in the United States last year.
Hemlibra is among the new medicines that the Basel-based pharmaceuticals maker hopes will offset falling sales of its three biggest drugs, Rituxan, Avastin, and Herceptin. Some analysts expect peak Hemlibra sales of more than $4 billion a year.
(Reporting by Silke Koltrowitz, Editing by Michael Shields)
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd